What You Should Know:
– EnsoData announces its official launch and a $9M Series A funding round to accelerate analysis and understanding of human health, starting with sleep disorder diagnoses.
– Using AI, EnsoData’s technology transforms billions of waveform data points (outputs from heartbeats on an EKG, eye movement through an EOG, brain waves through an EEG, etc.) collected from sensors in medical devices and wearables into an easy-to-read report.
– EnsoData saves clinics and health systems from spending thousands of hours reviewing data, which allows clinicians to reallocate time to what’s important to them – the patients and what’s literally keeping them up at night.
EnsoData, a Madison, WI-based company simplifying the process for analyzing the human body to accurately diagnose health conditions, announces its official launch with a $9 million Series A financing led by Venture Investors and Zetta Venture Partners. EnsoData partners with top clinicians, health systems, and academic medical centers to improve healthcare outcomes by streamlining data analysis with Waveform AI.
Empowering Clinicians with Waveform AI
Never has the need for systemic change to healthcare been more apparent – whether viewed through the lens of access, cost or business performance. Using artificial intelligence, EnsoData’s technology transforms billions of waveform data points collected from sensors in medical devices and wearables into an easy-to-read report, so clinicians can make faster, more accurate diagnoses. Waveforms are used in healthcare to diagnose, monitor, and treat patients. Heartbeats on an EKG, eye movements through an EOG, and brain waves through an EEG all output as waveform data, with over 1.5 billion waveforms run per year globally across specialties. EnsoData leads the world in reading and understanding these waveforms, starting with sleep.
Artificial Intelligence for Sleep Clinicians
People spend between one-third and one-quarter of their time on earth asleep, yet only recently did we begin to study its profound impact on our overall health and happiness. Sleep apnea is associated with increased risk for high blood pressure, heart problems, diabetes, depression, liver problems, complications with medications, surgeries, pregnancies, and issues with bed partners. It affects millions of Americans and costs the US nearly $150B per year — yet 80 percent of patients go undiagnosed and untreated. By analyzing the waveforms found in sleep studies, EnsoData is able to accurately detect and diagnose sleep apnea and its related conditions — at a drastically reduced cost and in substantially less time.
“Sleep apnea is a condition that plagues nearly one billion people worldwide, and we’re uniquely positioned to address this massive problem,” said Chris Fernandez, CEO of EnsoData. “We know that not everyone has access to quality and affordable treatment, and have the conviction that our technology can help bridge that gap. Automating waveform data analysis saves clinicians significant time, and labs and healthcare systems significant money, so they can focus on what really matters — the patients and what’s literally keeping them up at night.”
The capital will be used to launch new AI products in sleep and neurology; grow the company’s world-class team; expand diagnostic access and partnerships with leading sleep clinics, enterprise health systems, academic medical centers, home sleep testing providers, and integrated diagnostic testing facilities; and extend support for clinical trials that enable patient access to a new generation of effective, personalized medications and therapeutic devices.